Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Vanita Aroda MD

Vanita R. Aroda MD

Director, Diabetes Clinical Research, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Vanita Aroda is the Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, MA, and is Member of the Faculty of Harvard Medical School. Dr. Aroda completed her training in Internal Medicine and in Endocrinology, Diabetes and Metabolism at the University of California San Diego, CA, USA.

Dr. Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management. She also has a strong interest in understanding therapeutic interventions in large Phase 3 and 4 clinical trials and their applicability and integration into care. Dr. Aroda has years of experience in clinical trial conduct and leadership, has served as an investigator on the National Institutes of Health-funded GRADE, D2d, and DPPOS studies, and as the national or international signatory Principal Investigator for several phase 3 clinical trials.

Disclosures

Dr. Vanita Aroda reports the following:
  • Consultant: Adocia, Astra Zeneca, BD, Novo Nordisk, Sanofi, Zafgen
  • Employee: Merck Research Laboratories (Spouse)
  • Research Support: Astra Zeneca/BMS, Calibra, Eisai, Janssen, Novo Nordisk, Sanofi, Theracos

Recent Contributions to PracticeUpdate:

  1. Subcutaneously Administered Tirzepatide vs Semaglutide for Adults With Type 2 Diabetes
  2. Association of Daily Low-Dose Aspirin With Incident Type 2 Diabetes in Community-Dwelling Healthy Older Adults
  3. Serum Sex Hormone–Binding Globulin Is a Mediator of the Association Between Intrahepatic Lipid Content and Type 2 Diabetes
  4. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide
  5. Glucagonostatic GLP-1 Potency in Diabetic and Non-Diabetic Patients
  6. Tirzepatide vs Semaglutide in Patients With Type 2 Diabetes
  7. RCT of Semaglutide in Adults With Overweight or Obesity, and Type 2 Diabetes
  8. Glycemic Durability of Early Combination Therapy With Vildagliptin and Metformin vs Sequential Metformin Monotherapy in Newly Diagnosed Type 2 Diabetes
  9. Effect of Lorcaserin on Prevention and Remission of Type 2 Diabetes in Overweight and Obese Patients

Most Read This Week

Recently Updated